Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Chăm sóc dựa trên giá trị

  • Home
  • Chăm sóc dựa trên giá trị
Medicare’s Oncology Care Model Did Not Increase Systemic Therapy Starts and Was Linked to Lower Use in Poor-Prognosis Cancer
Posted innews Oncology Public Health

Medicare’s Oncology Care Model Did Not Increase Systemic Therapy Starts and Was Linked to Lower Use in Poor-Prognosis Cancer

Posted by MedXY By MedXY 05/05/2026
A matched difference-in-differences study found that the Oncology Care Model did not increase systemic therapy initiation overall and was associated with lower treatment initiation and lower spending in poor-prognosis cancers.
Read More
The Limits of Risk-Based Contracting: Dissecting Healthcare Utilization and Low-Value Service Trends in Medicare Advantage
Posted inMedical News news Public Health

The Limits of Risk-Based Contracting: Dissecting Healthcare Utilization and Low-Value Service Trends in Medicare Advantage

Posted by MedXY By MedXY 01/06/2026
This evidence-based review examines whether the transition to risk-based contracts in Medicare Advantage successfully reduces healthcare utilization and low-value care, highlighting the discrepancy between financial incentives and clinical practice changes.
Read More
  • Optimizing Smoking Cessation Interventions in Lung Cancer Screening: Insights from the CASTL Trial
  • Shared Genetic Foundations of Idiopathic Pulmonary Fibrosis in East Asian and European Populations
  • Synergistic Impact of Clonal Hematopoiesis and Genetic Predisposition on Age-Related Macular Degeneration Risk: Insights from a Large UK Biobank Cohort
  • Comparing Long-Term Systemic Risks of Biologic Versus Conventional Therapy in Non-Infectious Uveitis
  • Nicotinamide Supplementation and Primary Open-Angle Glaucoma in Patients With Ocular Hypertension: Evidence, Mechanisms, and Clinical Implications
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in